Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.

Also called NCT02049814

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 494 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02049814
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02049814. Randomized; no masking; primary purpose treatment. Start 2014-05-09 (actual); primary completion 2016-06-01 (actual). Results posted on 2019-02-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Metformin
Intervention (Drug)
Voglibose
Intervention (Drug)
Acarbose
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02049814
Content hash
bebb012757a53e6772b0e99884426c19a9205a60bd30c8aae2ec7c8f68eb6eb6